Evidence map›Paper›PMID 30004111›Full record

Trial reportBritish journal of haematology2018

Recipient single nucleotide polymorphisms in Paneth cell antimicrobial peptide genes and acute graft-versus-host disease: analysis of BMT CTN-0201 and -0901 samples.

Armin Rashidi, Ryan Shanley, Sophia L Yohe, Bharat Thyagarajan, Julie Curtsinger, Claudio Anasetti, Edmund K Waller, Bart L Scott, Bruce R Blazar, Daniel J Weisdorf

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Armin RashidiDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-9384-272X
Ryan ShanleyMasonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, MN, USA.
Sophia L YoheDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Bharat ThyagarajanDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Julie CurtsingerMasonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Claudio AnasettiMoffitt Cancer Center, Tampa, FL, USA.
Edmund K WallerDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Bart L ScottFred Hutchinson Cancer Research Center, University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle, WA, USA.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Daniel J WeisdorfDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USEmory University · USMoffitt Cancer Center · USSeattle Cancer Care Alliance · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
BMT CTN Core - University of MinnesotaUG1HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI Mark Juckett, Margaret L MacMillan · 2017 to 2026
$1.9M
Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesUG1HL109137 · NHLBI · WASHINGTON UNIVERSITY · PI Iskra Pusic · 2017 to 2026
$1.9M
Core Clinical Consortium for Blood and Marrow Transplant Clinical Trials NetworkUG1HL069301 · NHLBI · UNIVERSITY OF FLORIDA · PI HSU, JACK W · 2017 to 2023
$1.1M
NCATS NIH HHS UL1 TR000114NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS UG1 HL069290NHLBI NIH HHS UG1 HL069301NHLBI NIH HHS UG1 HL109137NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Host genetics shape the gut microbiota, and gut dysbiosis increases the risk of acute graft-versus-host disease (aGVHD). Paneth cells and microbiota have interactions that contribute to immune regulation. α-defensin-5 (HD5) and regenerating islet-derived protein 3 alpha (Reg3A) are the most abundant Paneth cell antimicrobial peptides (AMPs). We hypothesized that single nucleotide polymorphisms (SNPs) in the genes for HD5 (DEFA5) and Reg3A (REG3A) predict aGVHD risk. We analysed pre-transplant recipient peripheral blood mononuclear cell samples from randomized Blood and Marrow Transplant Clinical Trials Network (BMT CTN) studies 0201 (94 patients with bone marrow and 93 with peripheral blood grafts) and 0901 (86 patients with myeloablative and 77 with reduced-intensity conditioning; all using peripheral blood grafts). In multivariable analysis (with a SNP × graft source interaction term in CTN-0201 and a SNP × conditioning intensity term in CTN-0901), DEFA5 rs4415345 and rs4610776 were associated with altered incidence of aGVHD grade II-IV [rs4415345 G vs. C: hazard ratio (HR) 0·58, 95% confidence interval (95% CI) 0·37-0·92, P = 0·02; rs4610776 T vs. A: HR 1·53, 95% CI 1·01-2·32, P = 0·05] in CTN-0201, but not CTN-0901, suggesting a stronger effect in bone marrow allografts. REG3A SNP was not associated with aGVHD. Host genetics may influence aGVHD risk by modulating Paneth cell function.

Indexed as

Polymorphism, Single NucleotideAcute Diseasealpha-DefensinsAntimicrobial Cationic PeptidesBlood Specimen CollectionBone Marrow TransplantationClinical Trials as TopicGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHost Microbial InteractionsHumansMicrobiotaPancreatitis-Associated ProteinsPaneth CellsPrognosisalpha-DefensinsAntimicrobial Cationic PeptidesDEFA5 protein, humanPancreatitis-Associated ProteinsREG3A protein, humandefensinGVHDmicrobiotaReg3αSNP

Identifiers

PMID30004111
PMCPMC6128755
OpenAlexW2884761670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.